NDC properties for "Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream" (RxCUI 728126)
About this data
The tables show NDC propoerties for Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream with the RxCUI 728126
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream (RxCUI 728126)
| MMSL_CODE | BD28131 |
|---|---|
| RxCUI | 728126 |
| Prescribable Synonym | Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream |
| RXNAV_STR | Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream |
| RxNorm Name | lidocaine 70 MG/ML / tetracaine 70 MG/ML Topical Cream [Pliaglis] |
| RxNorm Synonym | Pliaglis (lidocaine 7 % / tetracaine 7 % ) Topical Cream |
| Related queries | Interactions (for RxCUI 728126) |
NDC Properties
NDC Item 00299610010
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-10 |
| NDC Item | 00299610010 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-35 |
| NDC Item | 00299610035 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
| NDC 9 | 51672-5305 |
|---|---|
| NDC 10 | 51672-5305-2 |
| NDC Item | 51672530502 |
| Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
| FDA SPL set id | 540569 |
| Labeler | Taro Pharmaceuticals U.S.A., Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-12-11 |
| Marketing status | ACTIVE |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-02 |
| NDC Item | 73575000902 |
| Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-04 |
| NDC Item | 73575000904 |
| Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-09 |
| NDC Item | 73575000909 |
| Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-10 |
| NDC Item | 00299610010 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-35 |
| NDC Item | 00299610035 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
| NDC 9 | 51672-5305 |
|---|---|
| NDC 10 | 51672-5305-2 |
| NDC Item | 51672530502 |
| Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
| FDA SPL set id | 540569 |
| Labeler | Taro Pharmaceuticals U.S.A., Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-12-11 |
| Marketing status | ACTIVE |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-02 |
| NDC Item | 73575000902 |
| Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-04 |
| NDC Item | 73575000904 |
| Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-09 |
| NDC Item | 73575000909 |
| Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-10 |
| NDC Item | 00299610010 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-35 |
| NDC Item | 00299610035 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
| NDC 9 | 51672-5305 |
|---|---|
| NDC 10 | 51672-5305-2 |
| NDC Item | 51672530502 |
| Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
| FDA SPL set id | 540569 |
| Labeler | Taro Pharmaceuticals U.S.A., Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-12-11 |
| Marketing status | ACTIVE |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-02 |
| NDC Item | 73575000902 |
| Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-04 |
| NDC Item | 73575000904 |
| Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-09 |
| NDC Item | 73575000909 |
| Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-10 |
| NDC Item | 00299610010 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-35 |
| NDC Item | 00299610035 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
| NDC 9 | 51672-5305 |
|---|---|
| NDC 10 | 51672-5305-2 |
| NDC Item | 51672530502 |
| Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
| FDA SPL set id | 540569 |
| Labeler | Taro Pharmaceuticals U.S.A., Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-12-11 |
| Marketing status | ACTIVE |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-02 |
| NDC Item | 73575000902 |
| Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-04 |
| NDC Item | 73575000904 |
| Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-09 |
| NDC Item | 73575000909 |
| Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-10 |
| NDC Item | 00299610010 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-35 |
| NDC Item | 00299610035 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
| NDC 9 | 51672-5305 |
|---|---|
| NDC 10 | 51672-5305-2 |
| NDC Item | 51672530502 |
| Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
| FDA SPL set id | 540569 |
| Labeler | Taro Pharmaceuticals U.S.A., Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-12-11 |
| Marketing status | ACTIVE |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-02 |
| NDC Item | 73575000902 |
| Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-04 |
| NDC Item | 73575000904 |
| Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-09 |
| NDC Item | 73575000909 |
| Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 00299610010
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-10 |
| NDC Item | 00299610010 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-10) / 100 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 00299610035
| NDC 9 | 0299-6100 |
|---|---|
| NDC 10 | 0299-6100-35 |
| NDC Item | 00299610035 |
| Packaging | 1 TUBE in 1 CARTON (0299-6100-35) / 30 g in 1 TUBE |
| FDA SPL set id | 127914 |
| Labeler | Galderma Laboratories, L.P. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2006-06-29 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 0299-6100 |
NDC Item 51672530502
| NDC 9 | 51672-5305 |
|---|---|
| NDC 10 | 51672-5305-2 |
| NDC Item | 51672530502 |
| Packaging | 1 TUBE in 1 CARTON (51672-5305-2) / 30 g in 1 TUBE |
| FDA SPL set id | 540569 |
| Labeler | Taro Pharmaceuticals U.S.A., Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2018-12-11 |
| Marketing status | ACTIVE |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 51672-5305 |
NDC Item 73575000902
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-02 |
| NDC Item | 73575000902 |
| Packaging | 2 TUBE in 1 CARTON (73575-009-02) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000904
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-04 |
| NDC Item | 73575000904 |
| Packaging | 4 TUBE in 1 CARTON (73575-009-04) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |
NDC Item 73575000909
| NDC 9 | 73575-009 |
|---|---|
| NDC 10 | 73575-009-09 |
| NDC Item | 73575000909 |
| Packaging | 1 TUBE in 1 CARTON (73575-009-09) / 30 g in 1 TUBE |
| FDA SPL set id | 500476 |
| Labeler | OBA PHARMACEUTICALS INC |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2020-01-24 |
| Marketing status | COMPLETED |
| NDA | NDA021717 |
| Related queries | Properties for NDC 9 73575-009 |